Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden

BACKGROUND: We aimed to investigate the cost effectiveness of lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), used first-line in Sweden to treat patients with ALK-positive (ALK+) non-small cell lung cancer (NSCLC). In January 2022, the European Medici...

Descripción completa

Detalles Bibliográficos
Autores principales: Naik, Jaesh, Beavers, Norma, Nilsson, Fredrik O. L., Iadeluca, Laura, Lowry, Chrissy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232573/
https://www.ncbi.nlm.nih.gov/pubmed/37173513
http://dx.doi.org/10.1007/s40258-023-00807-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232573/
https://www.ncbi.nlm.nih.gov/pubmed/37173513
http://dx.doi.org/10.1007/s40258-023-00807-7

Ejemplares similares